

Chapter 104

Psychocutaneous Skin Disease

Evan Rieder & Francisco A. Tausk

REFERENCES

1. Tausk F, Elenkov I, Moynihan J: Psychoneuroimmunology. *Dermatol Ther* 21(1):22-31, 2008
2. Tausk FA, Nousari H: Stress and the skin. *Arch Dermatol* 137(1):78-82, 2001
3. Gupta MA: Psychocutaneous disease. *Dermatol Clin* 4:591-745, 2005
4. Fritzsche K et al: Psychosomatic liaison service in dermatology. Need for psychotherapeutic interventions and their realization. *Dermatology* 203(1):27-31, 2001
5. Koblenzer C: *Psychosomatic Concepts in Dermatology*. Orlando, FL, Grune & Stratton, 1987
6. Harth W et al: *Clinical Management in Psychodermatology*, 1st edition. New York, Springer, 2008
7. DSM-IV: *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition. Washington, DC, American Psychiatric Association, 1994
8. Munro A: Monosymptomatic hypochondriacal psychosis. *Br J Psychiatry Suppl* (2):37-40, 1988
9. Musalek M, Kutzer E: The frequency of shared delusions in delusions of infestation. *Eur Arch Psychiatry Neurol Sci* 239(4):263-266, 1990
10. Wykoff RF: Delusions of parasitosis: A review. *Rev Infect Dis* 9(3):433-437, 1987
11. May WW, Terpenning MS: Delusional parasitosis in geriatric patients. *Psychosomatics* 32(1):88-94, 1991
12. Driscoll MS et al: Delusional parasitosis: A dermatologic, psychiatric, and pharmacologic approach. *J Am Acad Dermatol* 29(6):1023-1033, 1993
13. Gold PW, Goodwin FK, Chrousos GP: Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2) [published erratum appears in N Engl J Med 1988 Nov 24;319(21):1428]. *N Engl J Med* 319(7):413-420, 1988
14. Sandoz A et al: A clinical paradigm of delusions of parasitosis. *J Am Acad Dermatol* 59(4):698-704, 2008
15. Trabert W: 100 years of delusional parasitosis. Meta-analysis of 1,223 case reports. *Psychopathology* 28(5):238-246, 1995
16. Koblenzer CS: Pimozide at least as safe and perhaps more effective than olanzapine for treatment of Morgellons disease. *Arch Dermatol* 142(10):1364, 2006
17. Koo JY, Ng TC: Psychotropic and neurotropic agents in dermatology: Unapproved uses, dosages, or indications. *Clin Dermatol* 20(5):582-594, 2002
18. Lee CS: Delusions of parasitosis. *Dermatol Ther* 21(1):2-7, 2008
19. Harth W, Mayer K, Linse R: The borderline syndrome in psychosomatic dermatology. Overview and case report. *J Eur Acad Dermatol Venereol* 18(4):503-507, 2004
20. Jones DP: Dermatitis artefacta in mother and baby as child abuse. *Br J Psychiatry* 143:199-200, 1983
21. Krupp NE: Self-caused skin ulcers. *Psychosomatics* 18(2):15-19, 1977
22. Ozmen M et al: Dissociative identity disorder presenting as dermatitis artefacta. *Int J Dermatol* 45(6):770-771, 2006
23. Gieler U: Factitious disease in the field of dermatology. *Psychother Psychosom* 62(1-2):48-55, 1994
24. Garnis-Jones S, Collins S, Rosenthal D: Treatment of self-mutilation with olanzapine. *J Cutan Med Surg* 4(3):161-163, 2000
25. Koblenzer CS: Dermatitis artefacta. Clinical features and approaches to treatment. *Am J Clin Dermatol* 1(1):47-55, 2000
26. Christenson GA, Pyle RL, Mitchell JE: Estimated lifetime prevalence of trichotillomania in college students. *J Clin Psychiatry* 52(10):415-417, 1991
27. Schlosser S et al: The demography, phenomenology and family history of 22 persons with compulsive hair pulling. *Ann Clin Psychiatry* 6(3):147-152, 1994
28. Swedo SE, Leonard HL: Trichotillomania. An obsessive compulsive spectrum disorder? *Psychiatr Clin North Am* 15(4):777-790, 1992
29. Sah DE, Koo J, Price VH: Trichotillomania. *Dermatol Ther* 21(1):13-21, 2008

30. Bouwer C, Stein DJ: Trichobezoars in trichotillomania: Case report and literature overview. *Psychosom Med* **60**(5):658-660, 1998
31. Muller SA: Trichotillomania: A histopathologic study in sixty-six patients. *J Am Acad Dermatol* **23**(1):56-62, 1990
32. Christenson GA et al: A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. *Am J Psychiatry* **148**(11):1566-1571, 1991
33. Gupta MA, Gupta AK: Olanzapine is effective in the management of some self-induced dermatoses: Three case reports. *Cutis* **66**(2):143-146, 2000
34. Minichiello WE et al: Trichotillomania: Clinical aspects and treatment strategies. *Harv Rev Psychiatry* **1**(6):336-344, 1994
35. Ninan PT et al: A controlled trial of venlafaxine in trichotillomania: Interim phase I results. *Psychopharmacol Bull* **34**(2):221-224, 1998
36. Streichenwein SM, Thornby JI: A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. *Am J Psychiatry* **152**(8):1192-1196, 1995
37. Winchel RM et al: Clinical characteristics of trichotillomania and its response to fluoxetine. *J Clin Psychiatry* **53**(9):304-308, 1992
38. Cohen HA, Barzilai A, Lahat E: Hypnotherapy: An effective treatment modality for trichotillomania. *Acta Paediatr* **88**(4):407-410, 1999
39. Griesemer R: Emotionally triggered disease in a dermatology practice. *Psychiatric Ann* **8**:407-412, 1978
40. Koo J: Psychodermatology: A practical manual for clinicians. *Curr Probl Dermatol* **7**:199-234, 1995
41. Arnold LM, Auchenbach MB, McElroy SL: Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. *CNS Drugs* **15**(5):351-359, 2001
42. Gupta MA, Gupta AK, Haberman HF: Neurotic excoriations: A review and some new perspectives. *Compr Psychiatry* **27**(4):381-386, 1986
43. Fruensgaard K: Neurotic excoriations; a controlled psychiatric examination. *Acta Psychiatr Scand* **69**(Suppl.):1-52, 1984
44. Fried RG, Fried S: Picking apart the picker: A clinician's guide for management of the patient presenting with excoriations. *Cutis* **71**(4):291-298, 2003
45. Fruensgaard K: Psychotherapeutic strategy and neurotic excoriations. *Int J Dermatol* **30**(3):198-203, 1991
46. Fruensgaard K: Neurotic excoriations. A controlled psychiatric examination. *Acta Psychiatr Scand Suppl* **312**:1-52, 1984
47. Harth W, Taube KM, Gieler U: Factitious disorders in dermatology. *J Dtsch Dermatol Ges* **8**(5):361-372, 2010
48. Grant JE, Phillips KA: Recognizing and treating body dysmorphic disorder. *Ann Clin Psychiatry* **17**(4):205-210, 2005
49. Andreason N, Bardach J: Dismorphophobia: Symptom or disease? *Am J Psychiatry* **134**:673-676, 1977
50. McElroy SL et al: Body dysmorphic disorder: Does it have a psychotic subtype? *J Clin Psychiatry* **54**(10):389-395, 1993
51. Hollander E, Cohen L, Simeon D: Body dysmorphic disorder. *Psychiatric Ann* **23**(7):359-364, 1993
52. Phillips KA et al: Body dysmorphic disorder: An obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both? *J Clin Psychiatry* **56**(Suppl. 4):41-51; discussion 52, 1995
53. Phillips KA et al: Body dysmorphic disorder: 30 cases of imagined ugliness. *Am J Psychiatry* **150**(2):302-308, 1993
54. Koran LM et al: The prevalence of body dysmorphic disorder in the United States adult population. *CNS Spectr* **13**(4):316-322, 2008
55. Rief W et al: The prevalence of body dysmorphic disorder: A population-based survey. *Psychol Med* **36**(6):877-885, 2006
56. Cotterill JA: Dermatological non-disease: A common and potentially fatal disturbance of cutaneous body image. *Br J Dermatol* **104**(6):611-619, 1981
57. Phillips KA et al: Body dysmorphic disorder: Treating an underrecognized disorder. *Am J Psychiatry* **165**(9):1111-1118, 2008
58. Phillips KA et al: Suicidal ideation and suicide attempts in body dysmorphic disorder. *J Clin Psychiatry* **66**(6):717-725, 2005
59. Phillips KA: *Understanding Body Dysmorphic Disorder*. New York, Oxford University Press, 2009
60. Phillips KA, Hollander E: Treating body dysmorphic disorder with medication: Evidence, misconceptions, and a suggested approach. *Body Image* **5**(1):13-27, 2008
61. Ipser JC, Sander C, Stein DJ: Pharmacotherapy and psychotherapy for body dysmorphic disorder. *Cochrane Database Syst Rev* (1):CD005332, 2009

62. Hollander E et al: Clomipramine vs desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. *Arch Gen Psychiatry* 56(11):1033-1039, 1999
63. Hollander E et al: Fluvoxamine treatment of body dysmorphic disorder. *J Clin Psychopharmacol* 14(1):75-77, 1994
64. Hollander E et al: Treatment of body-dysmorphic disorder with serotonin reuptake blockers. *Am J Psychiatry* 146(6):768-770, 1989
65. Phillips KA: An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. *Psychopharmacol Bull* 32(1):175-180, 1996
66. Phillips KA et al: Effectiveness of pharmacotherapy for body dysmorphic disorder: A chart-review study. *J Clin Psychiatry* 62(9):721-727, 2001
67. Phillips KA, Dwight MM, McElroy SL: Efficacy and safety of fluvoxamine in body dysmorphic disorder. *J Clin Psychiatry* 59(4):165-171, 1998
68. Katon W, Egan K, Miller D: Chronic pain: Lifetime psychiatric diagnoses and family history. *Am J Psychiatry* 142(10):1156-1160, 1985
69. King RB: Neuropharmacology of depression, anxiety, and pain. *Clin Neurosurg* 28:116-136, 1981
70. Magni G: On the relationship between chronic pain and depression when there is no organic lesion. *Pain* 31(1):1-21, 1987
71. Lee CS, Koo J: Psychopharmacologic therapies in dermatology: An update. *Dermatol Clin* 23(4):735-744, 2005
72. Koo JYM, Lee CS: *Psychocutaneous Medicine*. New York, Marcel Dekker, 2003

